Elevated NRD1 metalloprotease expression plays a role in breast cancer growth and proliferation

Genes Chromosomes and Cancer

Volumn 50, Issue 10, 2011, Pages 837-847

  Choong, Lee Yee ^a,c   Lim, Shen Kiat ^a,c   Chen, Yunhao ^a   Loh, Marie Chiew Shia ^a   Toy, Weiyi ^a,c   Wong, Chow Yin ^b   Salto Tellez, Manuel ^a   Shah, Nilesh ^a   Lim, Yoon Pin ^a,c,d  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d BIOINFORMATICS INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN NRD1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; METALLOPROTEASES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TYROSINE; UP-REGULATION;

EID: 80051560282     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20905     Document Type: Article

References (35)

1. Alao JP, Lam EW, Ali S, Buluwela L, Bordogna W, Lockey P, Varshochi R, Stavropoulou AV, Coombes RC, Vigushin DM. 2004. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 10: 8094-8104.
2. Chen Y, Olopade OI. 2008. MYC in breast tumor progression. Expert Rev Anticancer Ther 8: 1689-1698.
3. Chen Y, Choong LY, Lin Q, Philp R, Wong CH, Ang BK, Tan YL, Loh MC, Hew CL, Shah N Druker BJ, Chong PK, Lim YP. 2007. Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics 6: 2072-2087.
4. Choong LY, Lim S, Chong PK, Wong CY, Shah N, Lim YP. 2010. Proteome-wide profiling of the MCF10AT breast cancer progression model. PLoS One 5: e11030.
5. Choong LY, Lim S, Loh MC, Man X, Chen Y, Toy W, Pan M, Chen CS, Poonepalli A, Hande MP, Tan PH, Tellez MS, Wong CY, Shah N, Druker BJ, Lim YP. 2007. Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: Implications in target-directed therapeutics. Mol Cancer Ther 6: 2828-2842.
6. Cleator S, Heller W, Coombes RC. 2007. Triple-negative breast cancer: Therapeutic options. Lancet Oncol 8: 235-244.
7. Dawson PJ, Wolman SR, Tait L, Heppner GH, Miller FR. 1996. MCF10AT: A model for the evolution of cancer from proliferative breast disease. Am J Pathol 148: 313-319.
8. Eldridge AG, Loktev AV, Hansen DV, Verschuren EW, Reimann JD, Jackson PK. 2006. The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1. Cell 124: 367-380.
9. Elston CW, Ellis IO. 1991. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19: 403-410.
10. Fatrai S, Elghazi L, Balcazar N, Cras-Meneur C, Krits I, Kiyokawa H, Bernal-Mizrachi E. 2006. Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes 55: 318-325.
11. Fernandopulle SM, Cher-Siangang P, Tan PH. 2006. Breast carcinoma in women 35 years and younger: A pathological study. Pathology 38: 219-222.
12. GeneCards. Available at: Accessed on October 10, 2010.
13. Greenbaum D, Colangelo C, Williams K, Gerstein M. 2003. Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol 4: 117.1-117.8.
14. Hayes DF, Thor AD. 2002. c-erbB-2 in breast cancer: Development of a clinically useful marker. Semin Oncol 29: 231-245.
15. Hospital V, Prat A. 2004. Nardilysin, a basic residues specific metallopeptidase that mediates cell migration and proliferation. Protein Pept Lett 11: 501-508.
16. Ju X, Katiyar S, Wang C, Liu M, Jiao X, Li S, Zhou J, Turner J, Lisanti MP, Russell RG, Mueller SC, Ojeifo J, Chen WS, Hay N, Pestell RG. 2007. Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 104: 7438-7443.
17. Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP. 2010. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 5: e9201.
18. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. 1996. Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616.
19. Lim YP, Low BC, Lim J, Wong ES, Guy GR. 1999. Association of atypical protein kinase C isotypes with the docker protein FRS2 in fibroblast growth factor signaling. J Biol Chem 274: 19025-19034.
20. Lim YP, Diong LS, Qi R, Druker BJ, Epstein RJ. 2003. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther 2: 1369-1377.
21. Miller FR. 2000. Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia 5: 379-391.
22. Miller FR, Soule HD, Tait L, Pauley RJ, Wolman SR, Dawson PJ, Heppner GH. 1993. Xenograft model of progressive human proliferative breast disease. J Natl Cancer Inst 85: 1725-1732.
23. Nishi E, Hiraoka Y, Yoshida K, Okawa K, Kita T. 2006. Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-alpha-converting enzyme. J Biol Chem 281: 31164-31172.
24. Olopade OI, Grushko TA, Nanda R, Huo D. 2008. Advances in breast cancer: Pathways to personalized medicine. Clin Cancer Res 14: 7988-7999.
25. Rhee DK, Park SH, Jang YK. 2008. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics 92: 419-428.
26. Salto-Tellez M, Lee SC, Chiu LL, Lee CK, Yong MC, Koay ES. 2004. Microsatellite instability in colorectal cancer: Considerations for molecular diagnosis and high-throughput screening of archival tissues. Clin Chem 50: 1082-1086.
27. Santner SJ, Dawson PJ, Tait L, Soule HD, Eliason J, Mohamed AN, Wolman SR, Heppner GH, Miller FR. 2001. Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat 65: 101-110.
28. Seidah NG, Prat A. 2002. Precursor convertases in the secretory pathway, cytosol and extracellular milieu. Essays Biochem 38: 79-94.
29. Starcevic SL, Elferink C, Novak RF. 2001. Progressive resistance to apoptosis in a cell lineage model of human proliferative breast disease. J Natl Cancer Inst 93: 776-782.
30. Starcevic SL, Diotte NM, Zukowski KL, Cameron MJ, Novak RF. 2003. Oxidative DNA damage and repair in a cell lineage model of human proliferative breast disease (PBD). Toxicol Sci 75: 74-81.
31. Strickland LB, Dawson PJ, Santner SJ, Miller FR. 2000. Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers. Breast Cancer Res Treat 64: 235-240.
32. Takahashi Y, Yamaoka K, Nishikawa M, Takakura Y. 2009. Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors. J Pharm Sci 98: 74-80.
33. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. 2003. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest 112: 1116-1124.
34. Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, De Wolf-Peeters C, Christiaens MR, Michiels L, Bouillon R, Verstuyf A. 2007. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor /progesterone receptor /HER-2 breast carcinomas. Cancer Res 67: 6574-6581.
35. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, van Spaendonk R, Wolman SR. 2006. High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96: 177-186.